Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04391595
Other study ID # 2019-07
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date July 8, 2020
Est. completion date February 2025

Study information

Verified date March 2024
Source St. Joseph's Hospital and Medical Center, Phoenix
Contact Phase 0 Navigator
Phone 602-406-8605
Email research@ivybraintumorcenter.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection. In the lead-in cohort, a total of 10 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered LY3214996 plus Abemaciclib prior to surgical resection of their tumor. If positive PK results are demonstrated in ≥50% of Phase 0 participants and at least 5 participants are enrolled into Phase 2, up to approximately 40 additional participants will be enrolled in the dose expansion cohort in order to achieve a total of 25 participants enrolled into Phase 2 (lead-in cohort + dose expansion).


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date February 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Prior resection of histologically diagnosed WHO Grade IV glioma defined as glioma participants who have progressed on or following standard (Stupp regimen) therapy, which included maximal surgical resection, temozolomide, and fractionated radiotherapy. 2. Recurrence must be confirmed by diagnostic biopsy with local pathology review or contrast-enhanced MRI. 3. Participants must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per RANO criteria. 4. Sufficient archival tissue available to confirm eligibility. 5. For gliomas, archival tissue must demonstrate: (a) RB positivity (=20%) on immunohistochemistry (IHC); or, no RB mutations on next-generation sequencing (NGS), (b) Chromosomal loss of CDKN2A/B/C; or, CDK4/6 amplification on array CGH or NGS, (c) pERK positivity (>30%) on IHC. 6. Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable). 7. Participant has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative(s), and assent if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness. 8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other procedures. 9. Age =18 at time of consent 10. Have a performance status (PS) =2 on the Eastern Cooperative Oncology (Group (ECOG) scale (Oken et al. 1982) 11. Ability to swallow oral medications. 12. Participant has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility): Adequate bone marrow function: - absolute neutrophil count =1,000/mcL - platelets (at time of surgery) =100,000/mcL - hemoglobin =8.0 g/dL Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion. Adequate hepatic function: - total bilirubin =1.5 X ULN Participants with Gilbert's syndrome with a total bilirubin =2.0 times ULN and direct bilirubin within normal limits are permitted. - AST(SGOT) =3 X institutional ULN - ALT(SGPT) =3 X institutional ULN 13. Confirmed negative serum pregnancy test (ß-hCG) before starting study treatment or participant or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause. 14. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 months after the end of treatment administration. 15. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 6 months after the end of treatment administration. 16. Agreement to adhere to Lifestyle Considerations throughout study duration 17. Participants who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade =1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to Day 1. A washout period of at least 21 days is required between last chemotherapy dose and Day 1 (provided the patient did not receive radiotherapy). 18. Participants who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and Day 1. Exclusion Criteria: 1. Current use of coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed. 2. Pregnancy or lactation. 3. Known allergic reactions to components of the abemaciclib or LY3214996. 4. Active infection or fever >38.5°C requiring systemic antibiotic, antifungal or antiviral therapy within 4 weeks of Day 1. 5. Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis. 6. Known active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment. 7. Have history of central or branch retinal artery or venous occlusion with significant vision loss or other retinal diseases that cause current visual impairment or would likely cause visual impairment over the time period of the study. 8. Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). 9. Prior therapy with any CDK4/6 inhibitor or any ERK1/2 inhibitor. Prior therapy is defined as a therapeutic dosing. 10. Treatment with another investigational drug or other intervention within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer. 11. Have a mean QT interval corrected for heart rate (QTc) of =470 milliseconds on screening electrocardiogram (ECG) as calculated using the Bazett's formula. 12. The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Abemaciclib
100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
LY3214996
400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.

Locations

Country Name City State
United States Chandler Regional Medical Center Chandler Arizona
United States St. Joseph's Hospital and Medical Center Phoenix Arizona
United States HonorHealth Scottsdale Osborn Medical Center Scottsdale Arizona

Sponsors (4)

Lead Sponsor Collaborator
Nader Sanai Barrow Neurological Institute, Eli Lilly and Company, Ivy Brain Tumor Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 0: Pharmacokinetic analysis of tumor tissue Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in enhancing and non-enhancing tumor tissue 8 hour
Primary Phase 0: Pharmacokinetic analysis of cerebrospinal fluid (CSF) Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in CSF 8 hour
Primary Pharmacokinetic analysis of plasma Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in plasma Day 6 at 0, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose
Primary Phase 2: Progression-free survival Phase 2: 6-month progression-free survival (PFS6) rate measured from time of surgery to date of recurrence up to 60 months
Secondary Phase 0: PD Analysis Phase 0: percentage of pRSK+, pERK+, pRB+, pFOXM1, MIB-1+ and Cleaved Caspase 3+ cells from the surgical tissue will be quantified and compared to baseline archival tissue. Intraoperatively
Secondary Number of Adverse Events Number of Adverse Events up to 30 days after the last study dose
Secondary Incidence of drug-related toxicity Drug-related toxicity up to 30 days after the last study dose
Secondary Incidence of treatment-emergent adverse events Treatment-emergent adverse events up to 30 days after the last study dose
Secondary Deaths Deaths up to 60 months
Secondary Incidence of clinical laboratory abnormalities per CTCAE Clinical laboratory abnormalities per CTCAE up to 30 days after the last study dose
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Withdrawn NCT02876003 - Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Phase 2

External Links